Department of Radiology and Research Institute of Radiology, University of Ulsan, College of Medicine, Songpa-Gu, Seoul, Korea
Br J Radiol. 2011 Jul;84(1003):612-20. doi: 10.1259/bjr/74430952. Epub 2010 Nov 16.
The purpose of this study was to determine the relative accuracies of mammography, sonography, MRI and clinical examination in predicting residual tumour size and pathological response after neoadjuvant chemotherapy for locally advanced or inflammatory breast cancer. Each prediction method was compared with the gold standard of surgical pathology.
43 patients (age range, 25-62 years; mean age, 42.7 years) with locally advanced or inflammatory breast cancer who had been treated by neoadjuvant chemotherapy were enrolled prospectively. We compared the predicted residual tumour size and the predicted response on imaging and clinical examination with residual tumour size and response on pathology. Statistical analysis was performed using weighted kappa statistics and intraclass correlation coefficients (ICC).
The ICC values between predicted tumour size and pathologically determined tumour size were 0.65 for clinical examination, 0.69 for mammography, 0.78 for sonography and 0.97 for MRI. Agreement between the response predictions at mid-treatment and the responses measured by pathology had kappa values of 0.28 for clinical examination, 0.32 for mammography, 0.46 for sonography and 0.68 for MRI. Agreement between the final response predictions and the responses measured by pathology had kappa values of 0.43 for clinical examination, 0.44 for mammography, 0.50 for sonography and 0.82 for MRI.
Predictions of response and residual tumour size made on MRI were better correlated with the assessments of response and residual tumour size made upon pathology than were predictions made on the basis of clinical examination, mammography or sonography. Thus, the evaluation of predicted response using MRI could provide a relatively sensitive early assessment of chemotherapy efficacy.
本研究旨在比较乳腺钼靶、超声、MRI 及临床检查在预测局部晚期或炎性乳腺癌新辅助化疗后肿瘤残留大小和病理反应方面的相对准确性,以手术病理为金标准。
前瞻性纳入 43 例(年龄 25-62 岁,平均年龄 42.7 岁)接受新辅助化疗的局部晚期或炎性乳腺癌患者。比较影像学和临床检查预测的肿瘤残留大小和反应与病理检查的肿瘤残留大小和反应。采用加权 Kappa 统计和组内相关系数(ICC)进行统计学分析。
临床检查、乳腺钼靶、超声和 MRI 预测肿瘤大小与病理检查确定的肿瘤大小之间的 ICC 值分别为 0.65、0.69、0.78 和 0.97。治疗中期预测的反应与病理测量的反应之间的一致性的 Kappa 值分别为临床检查 0.28、乳腺钼靶 0.32、超声 0.46 和 MRI 0.68。最终预测的反应与病理测量的反应之间的一致性的 Kappa 值分别为临床检查 0.43、乳腺钼靶 0.44、超声 0.50 和 MRI 0.82。
与基于临床检查、乳腺钼靶或超声的预测相比,MRI 预测肿瘤反应和残留肿瘤大小与病理评估的反应和残留肿瘤大小相关性更好。因此,使用 MRI 预测反应可提供一种相对敏感的化疗疗效早期评估方法。